[Chinese Guidelines on Perioperative Management of Resectable Esophageal Cancer (2023 edition)].

The standardization of surgical treatment has become indispensable in the overall outcome of esophageal cancer care in China, but there is a notable deficiency of clinical guidelines regarding esophageal surgery. The Chinese National Cancer Center organized esophageal surgery experts from the Chinese Association of Thoracic Surgeons (CATS), Chinese Society for Thoracic and Cardiovascular Surgery (CSTCVS), and Chinese Society for Disease of the Esophagus (CSDE) to develop and establish the Chinese Guidelines on Perioperative Management of Resectable Esophageal Cancer (2023 edition). This guideline comprehensively covers all aspects of surgical treatment for esophageal cancer, including conceptual clarification, preoperative diagnosis, clinical staging, indications for surgery, multidisciplinary comprehensive treatment, surgical treatment modalities, and perioperative management. A total of 39 critical clinical questions are categorized into six domains above. This guideline follows the globally accepted approach for developing recommendations and takes into account the most recent research evidence as well as China's unique national circumstances. Its main aim is to serve as a comprehensive resource for standardizing the diagnosis and surgical treatment of esophageal cancer in China, with the ultimate goal of substantially improving the overall outcomes.外科治疗的规范性关乎我国食管癌的总体疗效，然而国内尚缺乏以食管外科专业为主要内容的诊疗指南。由国家癌症中心牵头组织中国医师协会胸外科医师分会、中华医学会胸心血管外科学分会、国际食管疾病学会中国分会的食管外科专家，经过共识会议制订了《中国可切除食管癌围手术期诊疗实践指南（2023版）》。本指南涵盖了食管癌外科治疗临床实践各个方面，包括概念厘清、术前诊断及临床分期、手术适应证、多学科综合治疗、外科治疗方式及围手术期管理，共计6大类39项关键的临床问题。本指南应用国际规范的指南制订方法，基于最新研究证据和我国国情，以期为我国食管癌外科诊疗工作的规范开展提供参考，提升我国食管癌总体疗效。.